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Dissociation between the course of the hemodynamic and
antiproteinuric effects of angiotensin I converting enzyme
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Dissociation between the course of the hemodynamic and antiprotein-
uric effects of angiotensin I converting enzyme inhibition. Angiotensin I
converting enzyme inhibition (ACEi) has been shown to lower urinary
protein excretion in human renal disease. The mechanism of this
antiproteinuric effect is hypothesized to be mediated by changes in
renal hemodynamics. However, clinical studies suggest that the effect
on renal hemodynamics is fully established immediately after the start
of treatment, whereas others show the antiproteinuric effect to reach
maximum only after several weeks. To clarify this issue we studied the
course of renal hemodynamics, blood pressure and proteinuria during
28 days of ACEi (enalapril 10 mg oid) in nine patients with proteinuria
due to non-diabetic renal disease. The effect of ACEi on blood pressure
and renal hemodynamics was already maximal within few hours after
start of treatment, and remained stable thereafter: MAP was lowered
with 8.6 1.9%, 10.6 2.1%, 12.8 2.3%and 12.9 2,5%, while FF
fell 23.0 2.0%, 17.0 2.6%, 16.8 2.8% and 15.9 4.0% on days 1,
7, 14 and 28 of ACEi, respectively. However, the antiproteinuric effect
only gradually reached its maximum on day 28. Urinary protein
excretion decreased with 10.9 6.1%, 32.7 6.2%, 46.3 2.5% and
54.0 2.5% on days 1, 7, 14 and 28 of ACEi, respectively. After drug
withdrawal all parameters returned towards baseline. We conclude that
a dissociation occurs in the course of the ACEi induced effects on
hemodynamics and urinary protein excretion. Although the short-term
antiproteinuric effect of ACEi may be mediated through changes in
systemic and renal hemodynamics, during continued ACEi-treatment
the antiproteinuric effect appears to be at least partially mediated by
other, non-hemodynamic mechanisms.
Angiotensin I converting enzyme inhibition (ACEi) has been
shown to lower urinary protein excretion in human renal
disease [1]. The mechanism of this antiproteinunc effect is still
debated. The prevailing hypothesis, derived from animal stud-
ies, suggests a relation between the reduction in proteinuria and
the ACEi-induced changes in renal hemodynamics [2, 3]. These
changes in renal hemodynamics are most likely the result of a
reduced angiotensin II (Ang II) formation, thus affecting the
resistance of both the pre- and postglomerular vasculature
[2—5]. During ACEi glomerular filtration rate (GFR) remains
stable or is slightly reduced, while effective renal plasma flow
(ERPF) rises, thus resulting in a decrease in filtration fraction
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(FF) [6—11]. Indeed, several clinical studies found the antipro-
teinunc effect to coincide and correlate with the ACEi-induced
changes in renal bemodynamics [6, 7].
However, a direct causal relationship between the changes in
renal hemodynamics and the antiproteinuric effect may be
questioned. Firstly, we recently showed that systemic Ang II
infusion in proteinuric patients treated with long-term ACEi did
offset the renal hemodynamic effects of ACEi, whereas the
antiproteinuric effect was not affected [9]. Secondly, both
animal and human studies found the maximum antiproteinuric
response to ACEi to be reached only several weeks after
initiation of therapy [1, 12—16]. In contrast, other studies
showed that both the systemic and renal hemodynamic effects
are maximal within hours, and remain relatively stable at this
level [17—21]. Both observations make a direct relation between
ACEi-induced renal hemodynamic changes and the antipro-
teinuric effect questionable.
To clarify this issue, we studied the effects of four weeks of
treatment with the ACE inhibitor, enalapril, in nine proteinunc
patients with non-diabetic renal disease, comparing the course
of the effects on proteinuria, blood pressure and renal hemody-
namics.
Methods
Patients and protocol
Nine patients with non-diabetic, chronic renal disease were
enrolled in this study. Entry criteria were a creatinine clearance
of more than 50 mI/mm, stable proteinuna exceeding 2.5 grams
per day, and no need for diuretic treatment. Before entry all
medication was withdrawn for at least six weeks. Patients were
prescribed a 50 mmol sodium restricted diet. Subjects gave their
informed consent to participate in this protocol, which was
approved by the local Medical Ethical Committee.
The study was performed on an ambulatory basis. We studied
the first dose effects of ACEi on proteinuria, blood pressure and
renal hemodynamics, and subsequently we studied the effects
of continued ACEi treatment during 28 days on these parame-
ters in the same patients.
The first dose effects were studied on two study days sepa-
rated by one week. During the first study day the effects of
placebo were monitored for eight hours, whereas the effects of
ACEi were assessed on the second study day. On these study
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days an oral fluid load of tap water (375 ml) was given at 7:45
a.m., as well as a bolus injection of renal function tracers
followed by a constant infusion of these tracers and fluid
(dextrose 5%, 175 ml/hr) in the right antecubital vein. Through-
out the day patients remained in supine position, except when
voiding. Patients received a standardized meal every two hours
containing equal amounts of fluid, sodium, potassium, carbo-
hydrates and protein. The total amount of sodium and protein
equalled that of the prescribed diet during the rest of the study
protocol. After an equilibration period lasting from 7:45 to 10:00
a.m., in which a constant plasma level of renal function tracers
was achieved, baseline measurements were performed from
10:00 to 12:00 a.m. At 12:00 a.m. either placebo or 10 mg
enalaprilat was injected intravenously as a bolus during five
minutes. During baseline, and from 12:00 to 8:00 p.m., blood
pressure was measured every 10 minutes and blood (left ante-
cubital vein) and urine was obtained every hour for determina-
tion of proteinuria and renal hemodynamic parameters. At 7:45
a.m., 12:00a.m., 3:00p.m., and 6:00p.m. blood was drawn for
the determination of ACE activity and plasma Ang II concen-
tration.
Following the study day on which the first dose effects of
ACEi were monitored, patients were instituted on enalapril 10
mg oid for one month to assess the effects of continued ACEi
treatment. Patients were seen on days 7, 14 and 28 after the
initiation of therapy, and again four weeks after drug with-
drawal (recovery). Before each visit patients collected two
consecutive 24-hour urines. The mean value of these two
collections was further used for data evaluation. At each of
these visits renal function and blood pressure were measured
from 10:00 a.m. to 2:00 p.m. in an identical way as described
above. During these in-hospital study days patients took med-
ication at 8:00 a.m. Both before (7:45 a.m.) and after drug
administration (12:00 a.m.) blood was drawn for the determina-
tion of ACE activity and plasma Ang II concentration.
Laboratory procedures
Serum and urinary electrolytes, urea and creatinine were
determined with an automated multi-analyzer (SMA-C, Tech-
nicon®), while urinary protein was determined in each urine
sample with the pyrogallol red-molybdate method [22]. The
intra-assay coefficient of variation of this method is less than
3.3%, while the inter-assay coefficient of variation is less than
3.0%. Blood pressure was measured at 10 minute intervals with
an automated device (Dinamap®). MAP was calculated as the
sum of one-third of the systolic and two-thirds of the diastolic
blood pressure. The mean value of these blood pressure data
obtained during one hour periods was used for data analysis.
GFR and ERPF were measured according to a previously
described method using a constant infusion of 1251-iothalamate
and '311-hippuran, respectively [23]. The intra-patient day-to-
day coefficient of variation of this method was 2.2% for GFR
and 5.0% for ERPF. Filtration fraction was calculated as the
ratio of GFR and ERPF. Renovascular resistance (RVR) was
defined as MAP divided by ERPF. Serum ACE activity was
measured using an HPLC-assisted assay [24]. Plasma for the
Ang II level determination was drawn in prechilled glass tubes
containing 1, lO-phenantroline, EDTA and captopril to prevent
in vitro generation or degradation of Ang II. Blood was imme-
diately centrifuged at 4°C. Plasma was stored at —20°C until
Table 1. Patient characteristics at entry
Patient no. Sex
Age
years
DBP SBP
mm Hg
Ccr
mi/mm
.Proteinuria
g/day Diagnosis
I
2
3
4
5
6
7
8
9
M
M
M
F
M
M
M
M
F
29
30
53
23
30
60
27
20
25
61 124
74 129
85 136
84 132
100 158
83 138
63 114
69 137
65 114
143
171
119
60
53
132
168
59
158
7.1
16.5
3.4
5.1
6.2
8.7
2.8
5.8
4.3
MOP
IgA
MOP
FGS
FGS
FGS
MOP
FGS
MGP
Mean
sE
2F/7M 33.0
4.3
76.0 131.3
4.1 4.3
118.1
15.2
6.7
1.3
Abbreviations are: F, female; M, male; DBP, diastolic blood pres-
sure; SBP, systolic blood pressure; Ccr, creatinine clearance; MGP,
membranous glomemlopathy; IgA, IgA nephropathy; FGS, focal gb-
merulosclerosis.
analysis. The amount of Ang II was determined by radioimmu-
noassay [25]. Cross reactivity of the Ang II antibody with
angiotensin I is less than 0.1%, and 100% with angiotensin III.
The detection range of this assay is 2.5 to 200 fmollml with an
intra-assay coefficient of variation of 8%.
Data analysis
Data are expressed as mean standard error (SE), unless
otherwise indicated. The acute effects of placebo and ACEi are
expressed as a percentage change from the mean of the two
one-hour baseline values. To correct for possible bias intro-
duced by circadian variation of the various parameters, values
obtained during the eight hours after injection of placebo are
subtracted from values obtained during time-corresponding
periods on the ACEi study day.
To assess the effects of continued ACEi treatment, parame-
ters measured on study days 7, 14 and 28 are expressed as
percentage change from the value obtained during the baseline
placebo day. For this purpose, data collected between 10:00
a.m. and 2:00 p.m. were used.
Statistical analysis was performed by using a paired, non-
parametric ANOVA (Fnedmann) for repeated measurements,
and a paired Wilcoxon's signed rank test. Correlations between
percentage changes were calculated by Spearman's linear re-
gression analysis. Statistical significance was assumed at a 5%
level.
Results
Characteristics of patients entering the study are given in
Table 1. Nearly all patients were normotensive and had ne-
phrotic range proteinuria. None of these patients had edema.
No significant differences were observed in baseline values
(10:00 to 12:00 a.m.) between the two study days on which the
acute effects of placebo and ACEi were assessed. Placebo
administration induced only minor, non-significant fluctuations
in renal hemodynamics and blood pressure. Urinary protein
excretion, however, showed a significant decrease from base-
line 0.232 0.029 to a minimum of 0.203 0.022 g/hr after
placebo (P < 0.05). After intravenous administration of ACEi,
a small but significant fall in GFR from 102 14 to 95 13
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Fig. 1. The course ofthe first dose effects ofACEi (enalapril 10mg i.v.)
on (A) glomerular filtration rate (0, GFR), effective renal plasma flow(•, ERPF), filtration fraction (Li, FF), renovascular resistance (,
RVR), and (B) mean arterial pressure (•, MAP) and proteinuria (0,
Parameters are expressed as percentage change from the mean
of two one-hour baseline values. Data are given as placebo-corrected
values. GFR decreased significantly during the first two hours after
ACEI. All other parameters after administration of ACEi differed
significantly from baseline during every timepoint, except for protein-
uria, reaching significance at timepoint 13:30 and 15:30. Mean and
standard error are depicted.
mi/mm (P < 0.05) was observed during the first two hours.
ERPF showed a marked increase from baseline 506 90 to
maximal 643 112 mllmin (P < 0.05). This resulted in a
decrease in FF from baseline 22.0 1.5% to a minimum of 16.3
1.3% (P < 0.05) and a lowering of RVR from baseline 0.284
0.068 to a minimum of 0.196 0.043 (P < 0.05).Mean arterial
blood pressure fell significantly from 93.6 4.2 to 84.8 3.3
mm Hg. Urinary protein excretion was lowered from 0.227
0.033 to a minimum of 0.179 0.025 glhr (P < 0.05). Figure 1
shows the course of the placebo-corrected first dose effects of
ACEi. GFR fell with maximally 9.5 1.9% within the first hour
after administration of ACEi, then returned towards baseline.
ERPF increased by maximally 30.1 2.1% in the third hour
post-drug. FF fell with a nadir of 29.6 1.5% in the second
hour post-drug, while RVR showed the most pronounced effect
with a maximal percentage decrease of 32.8 2.6%. MAP was
lowered with maximally 11.0 2.1% after two to three hours,
and proteinuria decreased by maximally 15.1 3.7%. Figure 1
also shows the conformity of the curves of proteinuria and renal
hemodynamics, and the similarity in time point on which the
maximum response was reached. Indeed, during the eight hours
after ACEi the mean change in ERPF, FF and RVR on the one
side and urinary protein excretion on the other showed a
—40
ACEi (10mg i.v.)
ACEi (10 mg oid)
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-
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Fig. 2. The course ofthe effects of ACEi (enalapril 10 mg oid) on (A)
glomerular filtration rate (0, GFR), effective renal plasma flow (•,
ERPF), filtration fraction (Li, FF), renovascular resistance (•, RVR),
and (B) mean arterial pressure (•, MAP) and proteinuria (0, U,0,).
Parameters are expressed as percentage change from baseline values
obtained on day —7. This graph also shows on day 1 the placebo
corrected values obtained during the first four hours after enalapril
injection. All parameters during treatment differed significantly from
baseline, except for ERPF at day 28. None of the parameters showed a
further change after the initial changes on the first day of ACEi, except
for GFR at day 28 and proteinuria at days 7, 14 and 28. Proteinuria fell
even significantly further (days 7 and 14 vs. day 28). Mean and standard
error are depicted.
significant correlation (r = 0.725, P < 0.05; r = 0.90, P < 0.01;
r = 0.733, P < 0.05, respectively). The changes in proteinuria
versus MAP nearly reached significance (r = 0.66, P < 0.10),
while no correlation was found with GFR (r = 0.38, NS).
Plasma Ang II concentration fell after the first dose of ACEi
from baseline 10.5 1.2 to 4.6 1.1 (3 hrs postdrug) and 5.6
1.4 pmollliter (6 hrs postdrug), whereas during the placebo day
Ang II concentration remained stable (9.5 1.5, 9.0 1.4, 8.4
1.6 pmol/liter, respectively).
Table 2 shows the absolute values of study parameters
obtained during continued ACEi treatment. Mean percentage
changes from baseline are given in Figure 2. This figure also
contains information on the effects of the first dose of ACEi,
obtained during the first four hours after enalapril injection.
Both absolute values and percentage changes of renal hemody-
namics during continued ACEi treatment showed no further
change after the initial effect on day 1. Continued ACEi resulted
in a significant and stable decrease in MAP with 10.6 2.1%,
12.8 2.3 and 12.9 2.5% at days 7, 14 and 28, respectively.
The fall in blood pressure was never significantly different from
ACEi (10 mg i.v.)
A40
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Table 2. Effects of one month of ACEi
Baseline
day — 7
ACEi Recovery
day 56day 7 day 14 day 28
GFR mi/mEn 105.4 13.6 100.3 13.7 97.6 12.8 96.4 13.4 98.6 12.5
ERPF mI/mm 506 86 571 97 563 979a 533 87 492 85
FF% 23.1 1.8 18.9 1.Ia 19.0 l.3 19.0 1.Ia 22.1 1.5
RVR 1O mm Hg/mI/mm 283 68 210 44 211 44 211 41 279 63
MAP mm Hg 94.5 4.1 84.1 2.8a 81.9 2,4a 81.8 2.5k 92.1 3.4
Proteinuna g/day 6.7 1.3 4.3 0.7a 3.8 0.9 3.1 0.6 6.0 1.1
ACE activity U/liter 07:45 56.4 24.4 17.2 43a 16.1 3.0k 16.1 3.Oa 54.2 21.9
12:00 47.6 22.0 4.0 0.8 3.7 0.7 3.8 Q7aC 43.7 18.8c
Ang II pmol/liter 07:45 10.5 1.2 12.0 1.0 8.4 1.0 8.1 0.9 7.1 0.3a
12:00 9.5 1.5 6.2 0.8C 5.6 0.9 5.3 l.2 7.1 0.6
Measurements were performed at baseline, at day 7, 14 and 28 of ACEi, and 28 days after drug withdrawal (recovery). ACE activity and plasma
levels of angiotensin II were measured both before (07.45) and after (12:00) drug administration. Study parameters are given as mean SE.
Abbreviations are: GFR, glomerular filtration rate; ERPF, effective renal plasma flow; FF, filtration fraction; RVR, renal vascular resistance;
MAP, mean arterial pressure; ACE, angiotensin converting enzyme; Ang II, angiotensin II concentration.
a P < 0.05 compared to values obtained during baselineb P < 0.05 compared to values obtained during day 7
P < 0.05 compared to values obtained at 07:45 on the same day
the 8.6 2.0% decrease in blood pressure after acute adminis-
tration of ACEi. Urinary protein excretion, however, showing
an initial decrease of 10.9 4.6% after the first four hours after
the administration of ACEi, had decreased by 32.7 6.2% after
one week treatment, and fell significantly further to 46.3 2.5%
at day 14, and to 54.0 2.5% at day 28 after initiation of
therapy. At no timepoint during continued ACEi treatment was
a correlation found between the fall in fall in proteinuria and the
changes in ERPF, FF and RVR. Individual hemodynamic and
antiproteinuric responses are shown in Figure 3. The decrease
in serum ACE activity during continued ACEi was already
maximal after one week treatment, both in the pre- as well in
the post-medication sample, indicating that systemic ACE
activity was maximally inhibited within one week (Table 2).
Pre-medication levels of Ang II showed no significant differ-
ences between baseline, and days 7, 14 and 28 of ACEi and
recovery, whereas the fall in Ang II post-medication at days 7,
14 and 28 was similar to the fall after the first administration of
ACEi. After drug withdrawal all the above-mentioned parame-
ters returned towards baseline, and were not significantly
different from baseline, except for proteinuria. Dietary compli-
ance to the sodium restricted diet, as measured by urinary
sodium excretion, remained stable during the protocol (94 19
mmollday at baseline, 76 15, 70 10, 88 17, 93 17 at days
7, 14 and 28 of ACEi and at recovery, respectively).
Discussion
In the present study we show a clear dissociation between the
course of the renal hemodynamic and the antiproteinuric effects
of ACEi. Although the renal hemodynamic effect appeared to
be maximal within hours after the first administration of ACEi
and remained stable thereafter, the antiproteinuric effect
reached maximum only several weeks after the initiation of
therapy. This finding questions a direct causal relationship
between these two parameters and gives rise to the hypothesis
that the antiproteinuric effect of ACEi in non-diabetic renal
disease is mediated, at least partially, by non-hemodynamic
mechanisms.
present study the first dose of ACEi resulted in a small
temporary decrease in GFR, while ERPF increased markedly,
thus resulting in a lowering of the filtration fraction. Blood
pressure fell by maximally 11.0%. These findings are in accor-
dance with previous studies [26—28]. The acute placebo cor-
rected antiproteinuric effect in our study was maximally 15.1%.
Allon, Pasque and Rodriguez found a single oral dose of
captopril to induce a maximal reduction in urinary protein
excretion of approximately 25% in non-diabetic patients [27],
while Elving et al found a maximal 17.0% reduction in albumin-
uria in diabetic patients [28]. Both studies, however, were not
placebo corrected. Our non-placebo corrected study result of
22.0% decrease in proteinuria is quite comparable to their
results. That we found only a small mean decrease in protein-
uria after the first administration of ACEi might be partially
explained by the fact that patients did not show a homogenous
reaction. This latter observation, however, does not interfere
with our finding of the slow onset of the antiproteinuric effect,
because even in the patient with the quantitatively most out-
spoken antiproteinunc response to acute ACEi, this effect did
not exceed the patient's individual, nor the mean antiprotein-
uric effect at days 14 and 28 of ACEi. Also the magnitude of the
achieved effects after 28 days of continued ACEi treatment is
comparable to that observed in other reports. Several authors
found similar changes in renal hemodynamics and blood pres-
sure [6-11]. Moreover, others studying the course of the
hemodynamic effects during ACEi also show an immediate
change in blood pressure and renal hemodynamics, remaining
stable thereafter [17—21]. Also, the achieved antiproteinuric
response after 28 days ACEi corresponds with previous reports
[1]. Thus, both our first dose ACEi, as well as our continued
treatment data on renal hemodynamics, blood pressure and
proteinuria compare fairly well to data in literature. The most
important new observation remains that we are the first to
observe the discrepancy between the course of the antipro-
teinuric and the hemodynamic effects. The antiproteinuric
effect of ACEi appeared to be relatively small on the first day,
while it increased gradually, reaching a maximum after four
How do our data compare to those in literature? In the weeks treatment. The hemodynamic effects, however, occurred
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after two months of ACEi the renal hemodynamic effects can
still be offset by Ang II infusion, indicating that the renal
hemodynamic effect of continued ACEi appears to be still
dependent on inhibition of systemic Ang II [9]. However, he
showed in that study that Ang II infusion had no effect on
MAP proteinuria after prolonged ACEi. Thus, factors other than
systemic Ang II related changes in renal hemodynamics have to
explain the antiproteinuric effect during prolonged treatment.
This is in agreement with our finding that systemic Ang II levels
were maximally lowered within hours after the first dose of
ACEi, and remaining stable thereafter, whereas the antipro-
teinuric effect had a slow onset.
Although our study was not designed to disclose the mecha-
nism of the "additional" antiproteinuric effect, it is interesting
to speculate about its nature. Firstly, it could be that the
proteinuria lowering effect of ACEi is indirectly mediated by
RVR the effects on systemic or renal hemodynamics. The long-
standing changes in renal hemodynamics might result in slowly
appearing structural changes in the glomerular filtering barrier,
thus reducing protein leakage. Data supporting this hypothesis
are provided by Riser et al, who showed that glomerular
hypertension provoked increased extracellular matrix produc-
tion [29], while Rosenberg and Hostetter found that intrarenal
vasoconstriction is associated with expression of early growth
response genes [30]. Secondly, the antiproteinuric effect of
ACEi might be mediated by non-hemodynamic mechanisms
specific for this class of drugs. Ang II has been shown to
possess trophic qualities in vitro [31, 32]. Inhibition of the
Uprot formation of systemic Ang II might thus result in structural
changes in the filtration barrier. Indeed, some clinical studies
suggested these structural alterations [10, 33]. Lastly, one could
even question the role of systemic Ang II in this additional
antiproteinuric effect. It could well be that ACEi induces slowly
appearing effects on local hormonal systems, such as the
intrarenal RAS, or on other hormonal systems, such as the
kinin-kallikrein system [34]. However, a possible role for the
kinin-kallikrein system appears to be equivocal, as both animal
and preliminary clinical data show angiotensin II receptor
antagonism to induce similar effects as ACE-inhibition [35, 36].
In conclusion, our study shows that during ACEi a dissocia-
tion occurs between the course of the systemic and renal
hemodynamic effect on the one side and the course of the
antiproteinuric effect on the other. Whereas the changes in
hemodynamics were maximal within hours after initiation of
therapy, the antiproteinuric effect reached its maximum only
several weeks after start of treatment. This gives rise to the
hypothesis that the antiproteinuric effect of ACEi in non-
diabetic renal disease is, at least partially, mediated by non-
hemodynamic mechanisms. Future studies investigating the
qualities of the glomerular filtration barrier during acute and
long-term ACEi might resolve the question on the mechanism
of the antiproteinuric effect of ACEi.
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Fig. 3. The course of the effects of ACEi (enalapril 10 mg old) on
systemic hemodynamics (MAP, mean arterial pressure, A), renal
hemodynamics (RVR, renovascular resistance, 8) and proteinuria
(Uprot, C) in 9 patients. Each line represents a single patient. Parame-
ters are expressed as percentage change from baseline values obtained
on day —7.
immediately after the start of ACEi and remained more or less
stable during continued treatment.
The fact that we, and others [28] found a good correlation
between the first dose effects of ACEi on renal hemodynamics
on the one side and the antiproteinuric effect on the other is
compatible with the hypothesis that during acute ACEi, Ang II
deprivation is the common cause for both effects. Indeed, Navis
et al showed that Ang II infusion offsets the acute effect of
ACEi on renal hemodynamics [26]. Unfortunately, no data are
available to date on the effect of Ang II infusion on proteinuria
after a single administration of ACEi. During continued treat-
ment other factors appear to come into play. As far as renal
hemodynamics are concerned, Heeg et al showed that even
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